Published: Mon, July 09, 2018
Health Care | By Cedric Leonard

‘Mosaic’ HIV Vaccine Shows Promise In First Human Trial

‘Mosaic’ HIV Vaccine Shows Promise In First Human Trial

The co-author of this study, DR. Dan H. Barouch, at the Harvard Medical School, said in a statement, "I would say that we are pleased with these data so far, but we have to interpret the data cautiously".

Barouch, who is the lead author of the study, also warned, however, "The challenges in the development of an HIV vaccine are unprecedented, and the ability to induce HIV-specific immune responses does not necessarily indicate that a vaccine will protect humans from HIV infection". To date, the "mosaic" is one among the only five experimental HIV vaccines that have proceeded to efficacy human trials.

Only four vaccine concepts have made it to testing in humans, and only one provided any evidence of protection in an efficacy trial, but the effect was considered too low to make it available for use. In the phase one clinical trial, researchers focused on HIV-1.

Shown to be safe in humans, the candidate vaccine has now advanced to the next phase of the pre-approval trial process, and will be tested in 2,600 women in southern Africa to see whether it prevents HIV infection.

A key hurdle to HIV vaccine development has been the lack of direct comparability between clinical trials and preclinical studies.

A vaccine against HIV has been a real challenge for scientists, because of this virus many strains.

Dr Brady added that in the meantime there were already tools that were effective for preventing the disease from spreading, such as contraception and treatments for HIV-positive people that prevent them from passing on the virus.

The most effective combination was called the Ad26/Ad26 plus gp140 vaccine candidate - it protected two-thirds of the vaccinated monkeys against infection.

According to a study in The Lancet, a new HIV vaccine is now being tested and developed, showing promising results thus far.

Al-Shabab Launches Deadly Assaults in Somali Capital
Witnesses said some ministry staffers died or were injured while leaping from windows or walls in an effort to escape. Ambulance sirens echoed across the area as soldiers opened fire to disperse bystanders and motorists.

During the initial stages of the drug testing, the researchers have found that the drug can trigger an immune response when administered to humans.

The vaccine improved the immune responses against HIV during a clinical trial involving almost 40 healthy adults.

A vaccine has proven elusive as the human immunodeficiency virus (HIV) mutates easily and can hide away in cells, evading the immune system, only to re-emerge and spread years later.

The study selected participants from around the world, notably those from the United States, Thailand, South Africa, Uganda, and Rwanda.

Nearly 37 million people worldwide are living with HIV/AIDS, with an estimated 1.8 million new cases every year.

They were given four vaccinations over the course of 48 weeks.

All of the vaccine combinations produced an anti-HIV immune system response and were found to be safe.

"The road to the clinic is still unpredictable since the exact mode of action in humans is still unknown and the 67 percent protection in monkeys might not be replicable in humans", said George Williams Mbogo from the Burnet Institute in Australia, who wasn't involved in the study.

Like this: